Compare ASIX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | ADCT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.1M | 496.7M |
| IPO Year | N/A | 2020 |
| Metric | ASIX | ADCT |
|---|---|---|
| Price | $15.94 | $4.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $7.60 |
| AVG Volume (30 Days) | 493.9K | ★ 1.6M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 35.47 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $1,491,348,000.00 | $75,209,000.00 |
| Revenue This Year | $4.71 | $10.36 |
| Revenue Next Year | $4.59 | $3.87 |
| P/E Ratio | $8.49 | ★ N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $14.10 | $1.05 |
| 52 Week High | $32.58 | $4.80 |
| Indicator | ASIX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 55.08 |
| Support Level | $15.20 | $3.15 |
| Resistance Level | $17.29 | $4.32 |
| Average True Range (ATR) | 0.59 | 0.38 |
| MACD | 0.26 | 0.03 |
| Stochastic Oscillator | 47.31 | 77.98 |
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).